CA-CAVLI-WIRELESS
26.3.2024 10:21:33 CET | Business Wire | Press release
Cavli Wireless, a pioneer in the IoT solutions landscape, is all set to announce its flagship 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024. The event, held at the NürnbergMesse GmbH, Nürnberg, Germany, from April 9 to 11 in Hall 3, Booth 3-311. Embedded World event is known for being the largest trade fair for Embedded technology, showcasing the latest and greatest in electronic systems, distributed intelligence, IoT, energy efficiency, and more. The event represents the premier stage for global innovators like Cavli Wireless to showcase the innovative CQM220 to the world.
The CQM220 is the flagship 5G RedCap cellular IoT module from Cavli Wireless, compatible with 3GPP release 17 standards, specifically designed for advanced IoT and M2M applications. It delivers robust data bandwidth, reaching up to 226Mbps in downlink and 121Mbps in uplink, facilitating rapid and efficient data transfer. Available in LGA, PCIe Gen2, and M.2 form factors, the CQM220 ensures broad compatibility and flexibility across various industrial applications. Its optional integrated eSIM offers global connectivity through the Cavli Hubble Device and Connectivity management platform, making it a versatile solution for international deployment.
Moreover, the CQM220's optional integrated GNSS feature positions it as an ideal candidate for precise tracking applications, essential in sectors like Asset Tracking and Vehicular Telemetry Systems. Accompanied by a Linux-based OpenSDK, the module allows for application-specific coding directly on the device, eliminating the need for an external host MCU. This capability, combined with its high data throughput and global operability, makes the CQM220 an optimal choice for next-generation applications that demand speed, accuracy, and worldwide functionality.
The CQM220 module is set to supercharge a range of industries with its advanced connectivity. In Industry 4.0, the module's high data throughput, and integrated GNSS make it a linchpin for smart factories, facilitating real-time monitoring and control of machinery, and predictive maintenance, thereby enhancing efficiency and reducing downtime. For Smart City initiatives, the CQM220's global connectivity and robust bandwidth support the deployment of smart grids, intelligent transportation systems, and public safety networks, contributing to more efficient and responsive urban environments. In asset tracking, the precision of the integrated GNSS and the module's widespread connectivity ensure accurate, real-time location tracking of goods and equipment across borders, which is crucial for logistics, fleet management, and theft prevention. Across these applications, the CQM220 empowers industries to harness the full potential of seamless global connectivity, driving innovation and operational excellence.
The Cavli Hubble Stack further enhances the capabilities of the CQM220 by introducing remote diagnosis, monitoring, and debugging of the module through Hubble Lens, an advanced component of the Cavli Hubble IoT connectivity & modem management platform. This feature eliminates the necessity for physical intervention, simplifying the expansion of IoT solutions. Through strategic alliances with operators worldwide, Cavli has established a substantial presence, delivering unparalleled connectivity solutions that set new standards in service quality and cost-effectiveness.
John Mathew, the CEO and the Chief Technology Architect of Cavli Wireless, remarked, "Unveiling the CQM220 at Embedded World 2024 marks a pivotal point for our company. Our continuous commitment to superior performance and creativity in the field of intelligent cellular connections has culminated in the creation of this durable 5G RedCap module. It is characterized by its dependability, effectiveness, and the ability to provide uninterrupted connectivity worldwide. These features are the core aspects of the CQM220 and serve to set apart both the product and Cavli Wireless in the bustling market."
With the unveiling of the CQM220 at Embedded World 2024, Cavli Wireless reiterates its dedication to providing cost-effective, uninterrupted, and superior cellular IoT solutions. We encourage you to engage with our solution specialists to explore the ways the CQM220 can enhance your upcoming project. Embark on your path to dependable and effective connectivity with Cavli.
About Cavli Wireless
Cavli Wireless is a cellular IoT module manufacturer that combines IoT connectivity and data management into one platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite application development processes. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
The Embedded World Exhibition & Conference is a global platform for the embedded systems community, where professionals from around the world can connect and share knowledge. The event offers insights into the entire world of embedded systems, including hardware, software, tools, and services. It features a high-quality transfer of knowledge through top-class speakers, expert panels, and exhibitor forums.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326234488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom